Hangzhou Tigermed Consulting Co., Ltd
HNGZY
$3.96
-$0.1386-3.38%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -7.01% | -13.85% | -9.46% | -15.18% | -12.32% |
| Total Other Revenue | -- | 36.44% | -56.29% | 49.47% | -- |
| Total Revenue | -7.01% | -11.09% | -10.84% | -13.81% | -12.32% |
| Cost of Revenue | 4.66% | 8.43% | -4.95% | -15.76% | -9.69% |
| Gross Profit | -26.18% | -51.40% | -19.26% | -10.90% | -16.34% |
| SG&A Expenses | 1.28% | 25.98% | 4.06% | 15.05% | -3.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 24.33% | -102.25% | 134.11% | 328.60% | -530.90% |
| Total Operating Expenses | 3.58% | 9.64% | -4.15% | -9.37% | -9.09% |
| Operating Income | -48.48% | -105.98% | -30.17% | -27.62% | -23.05% |
| Income Before Tax | -60.88% | -343.69% | -43.85% | -67.24% | -45.28% |
| Income Tax Expenses | -33.31% | -36.86% | -45.57% | -37.62% | -24.36% |
| Earnings from Continuing Operations | -65.27% | -474.35% | -43.59% | -71.77% | -47.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 170.67% | 103.72% | 80.33% | 162.14% | -57,214.29% |
| Net Income | -30.52% | -382.15% | -33.98% | -69.58% | -60.59% |
| EBIT | -48.48% | -105.98% | -30.17% | -27.62% | -23.05% |
| EBITDA | -41.50% | -90.79% | -26.62% | -24.19% | -20.09% |
| EPS Basic | -30.59% | -383.33% | -33.38% | -69.37% | -61.04% |
| Normalized Basic EPS | 7.63% | -81.32% | -10.18% | -27.71% | -51.64% |
| EPS Diluted | -30.59% | -385.78% | -33.38% | -69.37% | -61.04% |
| Normalized Diluted EPS | 7.63% | -81.32% | -10.18% | -27.71% | -51.64% |
| Average Basic Shares Outstanding | 0.03% | -0.60% | -0.82% | -0.54% | 1.08% |
| Average Diluted Shares Outstanding | 0.03% | -0.60% | -0.82% | -0.54% | 1.08% |
| Dividend Per Share | -- | -47.01% | -- | -- | -- |
| Payout Ratio | 0.27% | -1.62% | 0.61% | 10.13% | 0.74% |